NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026
Heather H. Cheng, Veda N. Giri, Michael Goggins, Matthew B. Yurgelun, Beth Y. Karlan, Barbara S. Norquist, MB Daly, Tuya Pal, Zahraa AlHilli, Banu Arun, Jane Churpek, Sarah Colonna, Susan M. Domchek, Mauricio R. Escobar, Laura Fejerman, S Friedman, Andrea Hagemann, Ashley Hendrix, Dezheng Huo, Mollie L. Hutton, Nawal Kassem, Seema A. Khan, Allison W. Kurian, Christine Laronga, Julie S Mak, Kara N. Maxwell, Kevin McDonnell, Sofía D. Merajver, Jacqueline Mersch, Kenneth Offit, Jennifer K. Plichta, Dominique Rash, Gwen Reiser, Leigha Senter-Jamieson, K. McWeeney Shannon, Jeanna Welborn, Myra Wick, Marie Wood, Susan Darlow, Zeenat Diwan, Mary Dwyer
Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate are intended to serve as a resource for health care providers to identify individuals who may benefit from cancer risk assessment and genetic counseling and testing; help guide decisions related to genetic testing; and facilitate a multidisciplinary approach in the comprehensive care of individuals at increased risk for hereditary breast, ovarian, pancreatic, and prostate cancer. The current guidelines focus primarily on assessment of pathogenic and likely pathogenic (P/LP) variants associated with increased risk of breast, ovarian, pancreatic, and prostate cancer and recommended approaches to genetic counseling/testing and care strategies in individuals with these P/LP variants associated with increased risk of these cancers. These NCCN Guidelines Insights summarize the panel's most recent recommendations regarding screening for prostate cancer and pancreas cancer, as well as testing criteria for nonepithelial ovarian cancer.